Gilead 4Q Revenues:$7.3 billion (-14%) 4Q Earnings:$3.1 billion (-34%) FY Revenues:$30.4 billion (-7%) FY Earnings:$13.5 billion (-25%) Comments: Harvoni sales were down 34% to $9.1 billion for the year, and Solvaldi sales were $4.0 billion, down 10% due to lower sales and competition, partially offset by sales of Epclusa (sofosbuvir and velpatasvir), which was launched in 2016, with sales of $1.8 billion for the year. Truvada sales were $3.6 billion, up 3%. Atripla sales were $2....